[go: up one dir, main page]

ATE344026T1 - Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant - Google Patents

Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant

Info

Publication number
ATE344026T1
ATE344026T1 AT03761592T AT03761592T ATE344026T1 AT E344026 T1 ATE344026 T1 AT E344026T1 AT 03761592 T AT03761592 T AT 03761592T AT 03761592 T AT03761592 T AT 03761592T AT E344026 T1 ATE344026 T1 AT E344026T1
Authority
AT
Austria
Prior art keywords
renin inhibitor
surfactant
pharmaceutical formulation
formulation containing
physiologically tolerated
Prior art date
Application number
AT03761592T
Other languages
English (en)
Inventor
Jutta Riedl
Satish Kannah
Walter Dieterle
Original Assignee
Speedel Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Pharma Ag filed Critical Speedel Pharma Ag
Application granted granted Critical
Publication of ATE344026T1 publication Critical patent/ATE344026T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AT03761592T 2002-06-28 2003-06-25 Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant ATE344026T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH11242002 2002-06-28

Publications (1)

Publication Number Publication Date
ATE344026T1 true ATE344026T1 (de) 2006-11-15

Family

ID=29783980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761592T ATE344026T1 (de) 2002-06-28 2003-06-25 Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant

Country Status (11)

Country Link
US (1) US20050147629A1 (de)
EP (1) EP1517682B1 (de)
JP (1) JP4519640B2 (de)
AT (1) ATE344026T1 (de)
AU (1) AU2003255527A1 (de)
CY (1) CY1105934T1 (de)
DE (1) DE60309472T2 (de)
DK (1) DK1517682T3 (de)
ES (1) ES2276110T3 (de)
PT (1) PT1517682E (de)
WO (1) WO2004002466A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CN1910135A (zh) * 2004-01-23 2007-02-07 斯皮德尔实验股份公司 氨基醇衍生物及其作为血管紧张肽原酶抑制剂的活性
AR047447A1 (es) * 2004-01-23 2006-01-18 Speedel Experimenta Ag Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
AR050043A1 (es) 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
EP2062874B1 (de) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren und Zwischenprodukte für die Herstellung von Aliskiren
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031603A1 (de) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmazeutische Zusammensetzung eines Grundstoffs
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
DE60309472D1 (de) 2006-12-14
US20050147629A1 (en) 2005-07-07
WO2004002466A1 (en) 2004-01-08
JP4519640B2 (ja) 2010-08-04
JP2005533816A (ja) 2005-11-10
EP1517682A1 (de) 2005-03-30
EP1517682B1 (de) 2006-11-02
AU2003255527A1 (en) 2004-01-19
DK1517682T3 (da) 2007-02-26
PT1517682E (pt) 2007-02-28
DE60309472T2 (de) 2007-06-28
ES2276110T3 (es) 2007-06-16
CY1105934T1 (el) 2011-04-06

Similar Documents

Publication Publication Date Title
CY1105934T1 (el) Φαρμακευτικη συνθεση που αποτελειται απο αναστολεα πενινης μη πεπτιδιου και επιφανειοδραστικο παραγοντα
CY1120138T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας που περιλαμβανει μια στερεη διασπορα αναστολεα πρωτεασης toy hiv
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
TR200001810A3 (tr) Hemen Eriyen Oral Dozaj Formülasyonu.
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
BR0209020A (pt) Composição farmacêutica de polialilamina
EA200400471A1 (ru) Оральная дозированная форма пропиверина
IL176449A0 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
MXPA05005709A (es) Composiciones farmaceuticas que comprenden un compuesto farmacologico basico respectivamente acido, un agente tensioactivo y un acido hidrosoluble fisiologicamente tolerable respectivamente base.
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CA2484184A1 (en) Minoxidil foam formulation
PT1131050E (pt) Formulacoes galenicas que se desintegram rapidamente na boca e metodo para as preparar
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
EP1619180A4 (de) Casr-antagonist
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
HUP0301487A2 (hu) Piranon proteáz inhibitorok orális adagolású önemulgeáló formulációi
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
DE60236025D1 (de) Pharmazeutische zusammensetzung enthaltend l-arginin
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
RS51578B (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING TELITROMYCIN
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
DE602004017514D1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
GEP20043377B (en) Pharmaceutical Complex

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1517682

Country of ref document: EP